Hisamitsu Pharmaceutical Co Inc (JP:4530)
:4530
Want to see JP:4530 full AI Analyst Report?
Top Page
Hisamitsu Pharmaceutical Co
(4530)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥6,528.00
▲(62.39% Upside)
Action:DowngradedDate:04/15/26
The score is primarily supported by strong financial quality, especially the very conservative balance sheet and steady revenue trend. It is held back by uneven cash-flow conversion and a mixed technical picture with soft momentum, while valuation is moderate with a low dividend yield.
Positive Factors
Conservative balance sheet
Extremely low debt-to-equity provides durable financial flexibility and downside protection. This conservative financing profile reduces refinancing and solvency risk, enabling steady R&D, selective capex or M&A and stability through industry cycles over the medium term.
Negative Factors
Uneven free cash flow conversion
Volatile free cash flow despite positive operating cash flows makes funding allocation less predictable. Inconsistent FCF limits reliable dividends, buybacks or reinvestment in weaker years and increases execution risk for strategic investments over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Extremely low debt-to-equity provides durable financial flexibility and downside protection. This conservative financing profile reduces refinancing and solvency risk, enabling steady R&D, selective capex or M&A and stability through industry cycles over the medium term.
Read all positive factors
Hisamitsu Pharmaceutical Co (4530) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥440.70B
Dividend Yield2.43%
Average Volume (3M)139.59K
Price to Earnings (P/E)22.5
Beta (1Y)0.30
Revenue Growth4.50%
EPS Growth-9.33%
CountryJP
Employees2,759
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)102.79
Shares Outstanding75,164,894
10 Day Avg. Volume146,500
30 Day Avg. Volume139,593
Financial Highlights & Ratios
PEG Ratio-2.46
Price to Book (P/B)1.47
Price to Sales (P/S)2.64
P/FCF Ratio45.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)292.6
Revenue Forecast (FY)¥168.50B
Hisamitsu Pharmaceutical Co Business Overview & Revenue Model
Company Description
Hisamitsu Pharmaceutical Co., Inc. is a Japan-based company primarily engaged in the research, development, manufacturing, and marketing of pharmaceutical products, with a strong focus on transdermal drug delivery systems. The company operates in ...
How the Company Makes Money
Hisamitsu makes money mainly by selling pharmaceuticals and consumer healthcare products, with revenue generated from (1) domestic sales in Japan and (2) international sales through overseas subsidiaries and distribution partners. A key driver is ...
Hisamitsu Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
63
Positive
| Breakdown | TTM | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 154.86B | 163.02B | 156.01B | 141.71B | 128.33B | 120.19B |
| Gross Profit | 91.68B | 96.12B | 91.20B | 78.97B | 72.70B | 70.07B |
| EBITDA | 21.08B | 24.97B | 35.04B | 24.37B | 21.08B | 17.30B |
| Net Income | 19.53B | 19.16B | 21.76B | 13.97B | 11.74B | 9.66B |
Balance Sheet | ||||||
| Total Assets | 334.93B | 367.16B | 343.07B | 328.78B | 313.92B | 302.86B |
| Cash, Cash Equivalents and Short-Term Investments | 118.13B | 118.64B | 129.12B | 125.32B | 136.87B | 142.43B |
| Total Debt | 2.65B | 2.38B | 3.86B | 2.10B | 2.29B | 2.46B |
| Total Liabilities | 62.00B | 72.47B | 63.66B | 61.69B | 55.51B | 47.97B |
| Stockholders Equity | 270.38B | 291.82B | 276.83B | 264.88B | 256.37B | 253.17B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 9.48B | 5.14B | 5.26B | 4.87B | 15.59B |
| Operating Cash Flow | 0.00 | 17.48B | 18.77B | 18.19B | 12.73B | 19.20B |
| Investing Cash Flow | 0.00 | -16.87B | 17.56B | -2.51B | -23.87B | -13.06B |
| Financing Cash Flow | 0.00 | -20.20B | -15.85B | -16.69B | -14.69B | -15.19B |
Hisamitsu Pharmaceutical Co Technical Analysis
Positive
4020.00
Price Trends
6101.36
Negative
5591.42
Positive
4850.07
Positive
Market Momentum
-2.67
Negative
49.22
Neutral
29.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4530, the sentiment is Positive. The current price of 4020 is below the 20-day moving average (MA) of 6039.55, below the 50-day MA of 6101.36, and below the 200-day MA of 4850.07, indicating a neutral trend. The MACD of -2.67 indicates Negative momentum. The RSI at 49.22 is Neutral, neither overbought nor oversold. The STOCH value of 29.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4530.
Hisamitsu Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | ¥2.79T | 8.09 | 12.22% | 2.22% | 7.76% | 15.64% | |
77 Outperform | ¥322.62B | 9.44 | ― | 2.12% | 5.87% | -1.85% | |
69 Neutral | ¥279.33B | 7.12 | 9.05% | 3.30% | 10.31% | 8.54% | |
68 Neutral | ¥1.32T | 19.13 | 5.75% | 3.51% | 2.09% | -26.70% | |
66 Neutral | ¥440.70B | 22.45 | 7.11% | 2.43% | 4.50% | -9.33% | |
56 Neutral | ¥771.36B | 26.11 | 48.92% | ― | 21.65% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4530
Hisamitsu Pharmaceutical Co
6,040.00
1,666.09
38.09%
JP:4506
Sumitomo Dainippon Pharma Co
1,719.50
778.50
82.73%
JP:4523
Eisai Co
4,687.00
550.78
13.32%
JP:4507
Shionogi & Co
3,170.00
766.50
31.89%
JP:4540
Tsumura & Co
3,651.00
-488.15
-11.79%
JP:4516
Nippon Shinyaku Co., Ltd.
4,790.00
1,166.13
32.18%
Hisamitsu Pharmaceutical Co Corporate Events
Hisamitsu Pharmaceutical Proposes New Board Slate With Limited Changes
Apr 13, 2026
Hisamitsu Pharmaceutical has announced a slate of 10 director candidates for election at its May 28, 2026 annual general meeting of shareholders, as the terms of all current directors expire. The proposal largely maintains continuity in governance...
Hisamitsu Profit Slips as Revenue Rises Ahead of Taiyo Kosan-Led Delisting
Apr 13, 2026
Hisamitsu Pharmaceutical reported fiscal 2026 net sales of ¥163.0 billion, up 4.5% year on year, but operating profit fell 5.2% to ¥17.9 billion and profit attributable to owners of parent declined 11.9% to ¥19.2 billion, reflecting...
Hisamitsu to Cancel All Treasury Shares Ahead of Planned Share Consolidation
Mar 13, 2026
Hisamitsu Pharmaceutical will cancel 4,763,348 of its common treasury shares, representing 6.34% of its issued shares before cancellation, with a scheduled effective date of May 12, 2026. The move, which will reduce the total number of issued shar...
Hisamitsu Pharma Sets Shareholder Vote on Share Consolidation Ahead of Planned Delisting
Mar 13, 2026
Hisamitsu Pharmaceutical’s board has resolved to convene an extraordinary shareholders’ meeting on April 17, 2026 to vote on a share consolidation, abolition of share unit provisions, and amendments to its articles of incorporation. Th...
Taiyo Kosan Wins Control of Hisamitsu Pharmaceutical After Successful Tender Offer
Feb 20, 2026
Taiyo Kosan Co., Inc. has successfully completed its tender offer for Hisamitsu Pharmaceutical’s common stock, share acquisition rights and American Depositary Shares, which ran from January 7 to February 19, 2026. A total of 41,803,599 shar...
Hisamitsu Sets Record Date for Potential MBO-Linked Shareholder Meeting
Feb 13, 2026
Hisamitsu Pharmaceutical will set February 28, 2026, effectively February 27 due to the weekend, as the record date to determine shareholders eligible to vote at an extraordinary general meeting expected in mid-April. The move follows a tender off...
TAIYO KOSAN Amends Tender Offer Filing for Hisamitsu Pharmaceutical After U.S. Antitrust Waiting Period
Feb 3, 2026
Hisamitsu Pharmaceutical and its affiliate TAIYO KOSAN Co., Inc. announced that TAIYO KOSAN has filed an amendment to its tender offer registration statement for Hisamitsu’s common shares, share acquisition rights and American Depositary Rec...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.